Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05178316 · ClinicalTrials.gov registry record · Phase 2
A Study of JZP150 in Adults With Posttraumatic Stress Disorder
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 282
- Enrollment target
NCT05178316 is a Phase 2 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 282 participants.
The verdict
NCT05178316, a Phase 2 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 282 participants
- Enrollment target
Study Summary
This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP150 in the treatment of adult participants with post-traumatic stress disorder (PTSD).
Interventions
- DRUG Placebo
- DRUG JZP150
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2021-12-29 |
| Est. Completion | 2023-12-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05178316
The ClinicalTrials.gov registry entry for NCT05178316 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05178316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05178316 about?
NCT05178316 is a clinical study titled "A Study of JZP150 in Adults With Posttraumatic Stress Disorder". This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP150 in the treatment of adult participants with post-traumatic stress disorder (PTSD).
What is the current status of trial NCT05178316?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 282 participants. The study started on 2021-12-29. Estimated completion is 2023-12-05.
What interventions are being tested in trial NCT05178316?
The interventions under investigation include: Placebo (DRUG), JZP150 (DRUG).
Who is sponsoring clinical trial NCT05178316?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.